![Page 1: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/1.jpg)
Murinized BCR-ABL+ B-lineage Acute Lymphoblastic Leukemia
Santana SanchezFarrar Lab8/21/19
![Page 2: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/2.jpg)
Background
• B-ALL represents a cancer with very few nonsynonymous mutations suggesting that it is not a good candidate for treatment with checkpoint blockade-based immunotherapy
![Page 3: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/3.jpg)
t(9;22) translocation
BCR-ABLUncontrolled Proliferation
Wikipedia
![Page 4: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/4.jpg)
ABLBCR
Background
• B-ALL represents a cancer with very few nonsynonymous mutations suggesting that it is not a good candidate for treatment with checkpoint blockade-based immunotherapy• Peptides derived from BCR-ABL are antigenic
![Page 5: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/5.jpg)
Background
• B-ALL represents a cancer with very few nonsynonymous mutations suggesting that it is not a good candidate for treatment with checkpoint blockade-based immunotherapy• Peptides derived from BCR-ABL are antigenic• Previous model: Arf-/- Pre-B cells express human BCR-ABL fusion protein
recapitulates BCR-ABL+ B-ALL in an immunocompetent mouse (LM138 cells)
![Page 6: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/6.jpg)
Background
• B-ALL represents a cancer with very few nonsynonymous mutations suggesting that it is not a good candidate for treatment with checkpoint blockade-based immunotherapy
• Peptides derived from BCR-ABL are antigenic
• Previous model: Arf-/- Pre-B cells express human BCR-ABL fusion protein recapitulates BCR-ABL+ B-ALL in an immunocompetent mouse (LM138 cells)
• Manlove et al. 2016 showed that robust immunization with fusion peptide + checkpoint blockade led to significantly improved survival
![Page 7: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/7.jpg)
Background
• B-ALL represents a cancer with very few nonsynonymous mutations suggesting that it is not a good candidate for treatment with checkpoint blockade-based immunotherapy
• Peptides derived from BCR-ABL are antigenic
• Previous model: Arf-/- Pre-B cells express human BCR-ABL fusion protein recapitulates BCR-ABL+ B-ALL in an immunocompetent mouse (LM138 cells)
• Manlove et al. 2016 showed that robust immunization with fusion peptide + checkpoint blockade led to significantly improved survival
• What is the problem?
![Page 8: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/8.jpg)
Background
• B-ALL represents a cancer with very few nonsynonymous mutations suggesting that it is not a good candidate for treatment with checkpoint blockade-based immunotherapy
• Peptides derived from BCR-ABL are antigenic
• Previous model: Arf-/- Pre-B cells express human BCR-ABL fusion protein recapitulates BCR-ABL+ B-ALL in an immunocompetent mouse (LM138 cells)
• Manlove et al. 2016 showed that robust immunization with fusion peptide + checkpoint blockade led to significantly improved survival
• What is the problem?
![Page 9: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/9.jpg)
Background
• B-ALL represents a cancer with very few nonsynonymous mutations suggesting that it is not a good candidate for treatment with checkpoint blockade-based immunotherapy• Peptides derived from BCR-ABL are antigenic• Previous model: Arf-/- Pre-B cells express human BCR-ABL fusion protein
recapitulates BCR-ABL+ B-ALL in an immunocompetent mouse (LM138 cells)• Manlove et al. 2016 showed that robust immunization with fusion peptide
+ checkpoint blockade led to significantly improved survival • Because of discrepancies between human and mouse BCR and ABL protein
sequence there are multiple foreign epitopes on the BCR-ABL fusion protein that are potentially driving the antileukemia immune response seen in Manlove et al.
![Page 10: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/10.jpg)
Goal
• Generate muBCR-ABL+ B-ALL cell line• Proliferate independently in culture• Dependent on BCR-ABL tyrosine kinase activity • Pre-B cell phenotype• Recapitulate B-ALL in vivo
![Page 11: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/11.jpg)
muBCR-ABL
Primary Bone Marrow Cells
Retroviral plasmid
Arf-/-
![Page 12: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/12.jpg)
Cloning Strategy
muBCR-ABL geneblock 1 muBCR-ABL geneblock 2
NotI EcoRI
IRES Thy1.1
NotI EcoRI
Carrier Plasmid
Retrovirus
![Page 13: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/13.jpg)
muBCR-ABL
~20 days
Primary Bone Marrow Cells
muBCR-ABL
Retroviral plasmid
Arf-/-Arf-/-
ST26
![Page 14: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/14.jpg)
muBCR-ABL
~20 days
Characterize by Flow Cytometry
Characterize in vivo
In vitro studies
Primary Bone Marrow Cells
muBCR-ABL
Retroviral plasmid
Arf-/-Arf-/-
ST26
![Page 15: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/15.jpg)
Goal
• Generate muBCR-ABL+ B-ALL cell line• Proliferate independently in culture• Dependent on BCR-ABL tyrosine kinase activity • Pre-B cell phenotype• Recapitulate B-ALL in vivo
![Page 16: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/16.jpg)
ST26 Proliferation
![Page 17: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/17.jpg)
Goal
• Generate muBCR-ABL+ B-ALL cell line• Proliferate independently in culture• Dependent on BCR-ABL tyrosine kinase activity • Pre-B cell phenotype• Recapitulate B-ALL in vivo
![Page 18: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/18.jpg)
ST26 cells are sensitive to Abl kinase inhibitor Nilotinib
muBCR-ABL, ARF-/-(ST26)
huBCR-ABL, ARF-/-(LM138)
![Page 19: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/19.jpg)
Goal
• Generate muBCR-ABL+ B-ALL cell line• Proliferate independently in culture• Dependent on BCR-ABL tyrosine kinase activity • Pre-B cell phenotype• Recapitulate B-ALL in vivo
![Page 20: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/20.jpg)
Goal
• Generate muBCR-ABL+ B-ALL cell line• Proliferate independently in culture• Dependent on BCR-ABL tyrosine kinase activity • Pre-B cell phenotype
• B220+• BP1+• CD19+• IgM-
• Recapitulate B-ALL in vivo
![Page 21: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/21.jpg)
HSC MLP NF B
PreBlate
PreBearlyCLP DJ-
ProBGL-ProB
FoB
AA4.1B220CD43CD24BP-1c-kitIL-7RCD19CD25IgM
Phenotypic Fraction: A B/C C’ D E F
Surf
ace
Prot
eins
Hardy 2004, B cell Protocols
B cell lineage
![Page 22: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/22.jpg)
HSC MLP NF B
PreBlate
PreBearlyCLP DJ-
ProBGL-ProB
FoB
AA4.1B220CD43CD24BP-1c-kitIL-7RCD19CD25IgM
Phenotypic Fraction: A B/C C’ D E F
Surf
ace
Prot
eins
Hardy 2004, B cell Protocols
B cell lineage
![Page 23: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/23.jpg)
WT
BM
ST26
D “Pre-B” 78.6E-F 18.4
D-F “Pre-B”E-F 3.67
D “Pre-B” 95.2
B220
IgM
B220
B220
CD43 IgM
D-F “Pre-B”
B220
CD43
C-D
CD25
BP1
A-C’ “Pro-B”
C-D
CD25
BP1
D-F “Pre-B”
B220
CD43
A-C’ “Pro-B”
![Page 24: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/24.jpg)
Goal
• Generate muBCR-ABL+ B-ALL cell line• Proliferate independently in culture• Dependent on BCR-ABL tyrosine kinase activity • Pre-B cell phenotype
üB220+üBP1+üCD19+ü IgM-
![Page 25: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/25.jpg)
Goal
• Generate muBCR-ABL+ B-ALL cell line• Proliferate independently in culture• Dependent on BCR-ABL tyrosine kinase activity • Pre-B cell phenotype• Recapitulate B-ALL in vivo
![Page 26: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/26.jpg)
Conclusions
üGenerate muBCR-ABL+ B-ALL cell lineüProliferate independently in cultureüDependent on BCR-ABL tyrosine kinase activity üPre-B cell phenotype? Recapitulate B-ALL in vivo
![Page 27: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/27.jpg)
Future Direction
• Survival analysis• Perform flow cytometry analysis on in vivo ST26 cells• Determine how ST26 cells respond to robust immunization +
checkpoint blockade therapy
![Page 28: MurinizedBCR-ABL+ B-lineage Acute Lymphoblastic Leukemia€¦ · Santana Sanchez Farrar Lab 8/21/19. Background •B-ALL represents a cancer with very few nonsynonymous mutations](https://reader034.vdocuments.site/reader034/viewer/2022051903/5ff44499207b1e72a22a6171/html5/thumbnails/28.jpg)
Acknowledgements
Thank you to the Farrar Lab!Michael FarrarSean TracyCan HekimHrishi VenkateshRobin LeeLucy SjaastadDavid OwenLynn Heltemes HarrisGrey Hubbard
T35 Medical Student Summer Research ProgramDaniel L. Mueller
Stephanie Krischuk